[Problems in the current target therapy of malignancies]

Vopr Onkol. 2005;51(5):607-11.
[Article in Russian]
No abstract available

Publication types

  • Review

MeSH terms

  • Alemtuzumab
  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm / pharmacology
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Azathioprine / pharmacology
  • Benzamides
  • Bevacizumab
  • Cetuximab
  • Erlotinib Hydrochloride
  • Gefitinib
  • Humans
  • Imatinib Mesylate
  • Neoplasms / drug therapy*
  • Phthalazines / pharmacology
  • Piperazines / pharmacology
  • Pyridines / pharmacology
  • Pyrimidines / pharmacology
  • Quinazolines / pharmacology
  • Quinolones / pharmacology
  • Rituximab
  • Sesquiterpenes / pharmacology
  • Sesquiterpenes, Guaiane
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Benzamides
  • Phthalazines
  • Piperazines
  • Pyridines
  • Pyrimidines
  • Quinazolines
  • Quinolones
  • Sesquiterpenes
  • Sesquiterpenes, Guaiane
  • Bevacizumab
  • Alemtuzumab
  • Rituximab
  • ibritumomab tiuxetan
  • vatalanib
  • arglabin
  • Imatinib Mesylate
  • Erlotinib Hydrochloride
  • tositumomab I-131
  • tipifarnib
  • Azathioprine
  • Trastuzumab
  • Cetuximab
  • Gefitinib